Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
12. Dezember 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
InstaNatural Expands 5-Star Vitamin C Skincare Line with Broad Spectrum SPF Products
24. September 2024 08:04 ET
|
InstaNatural
InstaNatural is expanding its popular Vitamin C-infused skincare line to include three new suncare products.
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
19. September 2024 01:00 ET
|
Vidac Pharma Holding PLC
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class...
Leading Dermatologic Associations and Skin Cancer Prevention Organizations Urge U.S. Surgeon General to Renew Skin Cancer Call to Action
18. September 2024 12:46 ET
|
American Society for Dermatologic Surgery Association
Schaumburg, Ill., Sept. 18, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery Association (ASDSA), in conjunction with the American Academy of Dermatology Association (AAD), the...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31. Mai 2024 16:05 ET
|
Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08. Mai 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
SkinCure Oncology’s GentleCure™ Experience to be Featured in National Public Health PSA Series
08. Mai 2024 09:00 ET
|
SkinCure Oncology LLC
GentleCure will be recognized as an innovative healthcare technology in an upcoming public service announcement (PSA) about nonmelanoma skin cancer.
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
17. April 2024 10:15 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
Common Skin Cancer, Like Christie Brinkley’s, Can Often Be Cured Without Surgery
14. März 2024 17:42 ET
|
SkinCure Oncology LLC
Christie Brinkley was diagnosed with common skin cancer and her doctor “stitched me up to perfection,” but most such cancers can be cured without surgery.
Actinic Keratosis Treatment Market Size is projected to reach USD 9.22 billion by 2031, growing at a CAGR of 4.1%: Straits Research
14. März 2024 10:15 ET
|
Straits Research Private Limited
New York, United States, March 14, 2024 (GLOBE NEWSWIRE) -- The purpose of treating actinic keratosis, a skin condition induced by prolonged sun exposure, is to prevent these precancerous lesions...